154 related articles for article (PubMed ID: 34416708)
1. Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale.
Wang Y; Cuggia A; Pacis A; Boileau JC; Marcus VA; Gao ZH; Chong G; Foulkes WD; Zogopoulos G
J Natl Compr Canc Netw; 2021 Aug; 19(8):883-887. PubMed ID: 34416708
[TBL] [Abstract][Full Text] [Related]
2. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
[TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
4. Frequency of mismatch repair deficiency in pancreatic ductal adenocarcinoma.
Ahmad-Nielsen SA; Bruun Nielsen MF; Mortensen MB; Detlefsen S
Pathol Res Pract; 2020 Jun; 216(6):152985. PubMed ID: 32360245
[TBL] [Abstract][Full Text] [Related]
5. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.
Hu ZI; Shia J; Stadler ZK; Varghese AM; Capanu M; Salo-Mullen E; Lowery MA; Diaz LA; Mandelker D; Yu KH; Zervoudakis A; Kelsen DP; Iacobuzio-Donahue CA; Klimstra DS; Saltz LB; Sahin IH; O'Reilly EM
Clin Cancer Res; 2018 Mar; 24(6):1326-1336. PubMed ID: 29367431
[No Abstract] [Full Text] [Related]
6. Comprehensive Mutation Analysis of PMS2 in a Large Cohort of Probands Suspected of Lynch Syndrome or Constitutional Mismatch Repair Deficiency Syndrome.
van der Klift HM; Mensenkamp AR; Drost M; Bik EC; Vos YJ; Gille HJ; Redeker BE; Tiersma Y; Zonneveld JB; García EG; Letteboer TG; Olderode-Berends MJ; van Hest LP; van Os TA; Verhoef S; Wagner A; van Asperen CJ; Ten Broeke SW; Hes FJ; de Wind N; Nielsen M; Devilee P; Ligtenberg MJ; Wijnen JT; Tops CM
Hum Mutat; 2016 Nov; 37(11):1162-1179. PubMed ID: 27435373
[TBL] [Abstract][Full Text] [Related]
7. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
[TBL] [Abstract][Full Text] [Related]
8. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer.
Kastrinos F; Steyerberg EW; Balmaña J; Mercado R; Gallinger S; Haile R; Casey G; Hopper JL; LeMarchand L; Lindor NM; Newcomb PA; Thibodeau SN; Syngal S;
Gut; 2013 Feb; 62(2):272-9. PubMed ID: 22345660
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Lynch syndrome among patients with upper urinary tract carcinoma in a Japanese hospital-based population.
Ito T; Kono K; Eguchi H; Okazaki Y; Yamamoto G; Tachikawa T; Akagi K; Okada Y; Kawakami S; Morozumi M; Tamaru JI; Ishida H
Jpn J Clin Oncol; 2020 Jan; 50(1):80-88. PubMed ID: 31665498
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Lupinacci RM; Goloudina A; Buhard O; Bachet JB; Maréchal R; Demetter P; Cros J; Bardier-Dupas A; Collura A; Cervera P; Scriva A; Dumont S; Hammel P; Sauvanet A; Louvet C; Delpéro JR; Paye F; Vaillant JC; André T; Closset J; Emile JF; Van Laethem JL; Jonchère V; Abd Alsamad I; Antoine M; Rodenas A; Fléjou JF; Dusetti N; Iovanna J; Duval A; Svrcek M
Gastroenterology; 2018 Mar; 154(4):1061-1065. PubMed ID: 29158190
[TBL] [Abstract][Full Text] [Related]
12. Four novel germline mutations in the MLH1 and PMS2 mismatch repair genes in patients with hereditary nonpolyposis colorectal cancer.
Montazer Haghighi M; Radpour R; Aghajani K; Zali N; Molaei M; Zali MR
Int J Colorectal Dis; 2009 Aug; 24(8):885-93. PubMed ID: 19479271
[TBL] [Abstract][Full Text] [Related]
13. The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer.
Halvarsson B; Lindblom A; Rambech E; Lagerstedt K; Nilbert M
Fam Cancer; 2006; 5(4):353-8. PubMed ID: 16817031
[TBL] [Abstract][Full Text] [Related]
14. The coding microsatellite mutation profile of PMS2-deficient colorectal cancer.
Bajwa-Ten Broeke SW; Ballhausen A; Ahadova A; Suerink M; Bohaumilitzky L; Seidler F; Morreau H; van Wezel T; Krzykalla J; Benner A; de Miranda NF; von Knebel Doeberitz M; Nielsen M; Kloor M
Exp Mol Pathol; 2021 Oct; 122():104668. PubMed ID: 34302852
[TBL] [Abstract][Full Text] [Related]
15. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
[TBL] [Abstract][Full Text] [Related]
16. The diversity of tumours with microsatellite instability: molecular mechanisms and impact upon microsatellite instability testing and mismatch repair protein immunohistochemistry.
Shia J
Histopathology; 2021 Mar; 78(4):485-497. PubMed ID: 33010064
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
[TBL] [Abstract][Full Text] [Related]
18. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
[TBL] [Abstract][Full Text] [Related]
20. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]